Battered by the midterms, abortion foes turn the screws on the GOP

Mother Jones
Original Story by Mother Jones
November 16, 2026
Battered by the midterms, abortion foes turn the screws on the GOP

In the wake of a painful midterm for their movement, anti-abortion leaders have intensified pressure on the Trump administration and a Republican-led Congress to crack down on abortion pills, including pressuring for delays to FDA nominee Heidi Overton and demanding the suspension of telehealth access to mifepristone. They argue for reforms to the agency’s safety review of the drug, framing current rules as a strategic vulnerability. By contrast, Democratic gains threaten to expand reproductive rights at the state level, with governors and legislatures poised to roll back restrictions and enshrine protections. The unfolding clash centers on how to curb pill access versus protecting abortion rights, with the next steps likely determining the political viability of hardline anti-abortion tactics and the administration’s approach to enforcement.

Dive Deeper:

  • Anti-abortion leaders, led by groups like Susan B. Anthony Pro-Life America, blamed the midterm results on a lack of abortion-related voting pressure and urged Republican senators to delay the FDA confirmation of Heidi Overton unless the administration commits to immediate suspension of Biden-era rules that allow mail-order mifepristone.

  • They also demanded the FDA commit to reforms in the ongoing safety review of mifepristone, a study the agency has delayed to 2027, arguing the current process is flawed and a delaying tactic to ride out midterms.

  • Overton’s background includes anti-abortion positions and involvement in vaccine policy debates; her confirmation faces scrutiny from lawmakers like Bill Cassidy, raising doubts about a likely party-line vote and a potential single GOP defection.

  • The article notes that after Dobbs, abortion pills have transformed access, with roughly 15,000 patients using the medication monthly and pills accounting for about two-thirds of abortions in the U.S., aided by rules removing in-person dispensing requirements.

  • Meanwhile, Democratic winners in several states are expected to roll back restrictions and codify reproductive rights, with Texas seeing a notable shift as Democratic leadership gains leverage, including moves to stop lawsuits against providers and agencies like the FDA.

  • Red states have filed multiple lawsuits challenging mifepristone regulation, while the administration defends the current mail-order regime; some observers view the push for Comstock Act enforcement as high-risk politically for Trump and allies.

Latest News

Related Stories